| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
Sunnybrook and Women's College Health Sciences Centre S-217, Toronto, Ontario, Canada; and Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
Requests for reprints: Robert S. Kerbel, Sunnybrook and Women's College Health Sciences Centre S-217, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. Phone: 416-480-5711; Fax: 416-480-5884; E-mail: Robert.kerbel{at}swri.ca.
Metronomic antiangiogenic chemotherapy, the prolonged administration of relatively low drug doses, at close regular intervals with no significant breaks, has been mainly studied at the preclinical level using single chemotherapeutic drugs, frequently in combination with a targeted antiangiogenic drug, and almost always evaluated on primary localized tumors. We tested a "doublet" combination metronomic chemotherapy treatment using two oral drugs, UFT, a 5-fluorouracil (5-FU) prodrug administered by gavage, and cyclophosphamide, for efficacy and toxicity in a new mouse model of advanced, terminal, metastatic human breast cancer. The optimal biological dose of each drug was first determined by effects on levels of circulating endothelial progenitor cells as a surrogate marker for angiogenesis, which was assessed to be 15 mg/kg for UFT and 20 mg/kg for cyclophosphamide. A combination treatment was then evaluated in mice with advanced metastatic disease using a serially selected metastatic variant of the MDA-MB-231 breast cancer-cell line, 231/LM2-4. UFT or cyclophosphamide treatment showed only very modest survival advantages whereas a combination of the two resulted in a remarkable prolongation of survival, with no evidence of overt toxicity despite 140 days of continuous therapy, such that a significant proportion of mice survived for over a year. In contrast, this striking therapeutic effect of the combination treatment was not observed when tested on primary orthotopic tumors. We conclude that combination oral low-dose daily metronomic chemotherapy, using cyclophosphamide and UFT, is superior to monotherapy and seems to be a safe and highly effective experimental antimetastatic therapy, in this case, for advanced metastatic breast cancer. (Cancer Res 2006; 66(7): 3386-91)
This article has been cited by other articles:
|
|
 |
|
  G. Francia, S. Man, C.-J. Lee, C. R. Lee, P. Xu, M. E. Mossoba, U. Emmenegger, J. A. Medin, and R. S. Kerbel Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2-Positive Human Breast Cancer Xenografts Clin. Cancer Res., October 15, 2009; 15(20): 6358 - 6366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Daenen, Y. Shaked, S. Man, P. Xu, E. E. Voest, R. M. Hoffman, D. J. Chaplin, and R. S. Kerbel Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models Mol. Cancer Ther., October 1, 2009; 8(10): 2872 - 2881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Maher, J. Mietz, C. L. Arteaga, R. A. DePinho, and S. Mohla Brain Metastasis: Opportunities in Basic and Translational Research Cancer Res., August 1, 2009; 69(15): 6015 - 6020. [Full Text] [PDF]
|
|
|
|
|
|
W. Cruz-Munoz, S. Man, and R. S. Kerbel Effective Treatment of Advanced Human Melanoma Metastasis in Immunodeficient Mice Using Combination Metronomic Chemotherapy Regimens Clin. Cancer Res., August 1, 2009; 15(15): 4867 - 4874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Watanabe, M. Sano, S. Takashima, T. Kitaya, Y. Tokuda, M. Yoshimoto, N. Kohno, K. Nakagami, H. Iwata, K. Shimozuma, et al. Oral Uracil and Tegafur Compared With Classic Cyclophosphamide, Methotrexate, Fluorouracil As Postoperative Chemotherapy in Patients With Node-Negative, High-Risk Breast Cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial J. Clin. Oncol., March 20, 2009; 27(9): 1368 - 1374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dellapasqua, F. Bertolini, V. Bagnardi, E. Campagnoli, E. Scarano, R. Torrisi, Y. Shaked, P. Mancuso, A. Goldhirsch, A. Rocca, et al. Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer J. Clin. Oncol., October 20, 2008; 26(30): 4899 - 4905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-Y. Zhao, A. Ooyama, M. Yamamoto, R. Ikeda, M. Haraguchi, S. Tabata, T. Furukawa, X.-F. Che, S. Zhang, T. Oka, et al. Molecular Basis for the Induction of an Angiogenesis Inhibitor, Thrombospondin-1, by 5-Fluorouracil Cancer Res., September 1, 2008; 68(17): 7035 - 7041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Cruz-Munoz, S. Man, P. Xu, and R. S. Kerbel Development of a Preclinical Model of Spontaneous Human Melanoma Central Nervous System Metastasis Cancer Res., June 15, 2008; 68(12): 4500 - 4505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamauchi, M. Yang, K. Hayashi, P. Jiang, N. Yamamoto, H. Tsuchiya, K. Tomita, A. R. Moossa, M. Bouvet, and R. M. Hoffman Induction of Cancer Metastasis by Cyclophosphamide Pretreatment of Host Mice: An Opposite Effect of Chemotherapy Cancer Res., January 15, 2008; 68(2): 516 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M.L. Ebos, C. R. Lee, E. Bogdanovic, J. Alami, P. Van Slyke, G. Francia, P. Xu, A. J. Mutsaers, D. J. Dumont, and R. S. Kerbel Vascular Endothelial Growth Factor Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth Cancer Res., January 15, 2008; 68(2): 521 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ma and D. J. Waxman Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment Mol. Cancer Ther., November 1, 2007; 6(11): 2879 - 2890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Bell-McGuinn, A. L. Garfall, M. Bogyo, D. Hanahan, and J. A. Joyce Inhibition of Cysteine Cathepsin Protease Activity Enhances Chemotherapy Regimens by Decreasing Tumor Growth and Invasiveness in a Mouse Model of Multistage Cancer Cancer Res., August 1, 2007; 67(15): 7378 - 7385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Suvannasankha, C. Fausel, B. E. Juliar, C. T. Yiannoutsos, W. B. Fisher, R. H. Ansari, L. L. Wood, G. G. Smith, L. D. Cripe, and R. Abonour Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial, HEM01-21 Oncologist, January 1, 2007; 12(1): 99 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S.W. Ng, A. Sparreboom, Y. Shaked, C. Lee, S. Man, N. Desai, P. Soon-Shiong, W. D. Figg, and R. S. Kerbel Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL-Based Paclitaxel. Clin. Cancer Res., July 15, 2006; 12(14): 4331 - 4338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mancuso, M. Colleoni, A. Calleri, L. Orlando, P. Maisonneuve, G. Pruneri, A. Agliano, A. Goldhirsch, Y. Shaked, R. S. Kerbel, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy Blood, July 15, 2006; 108(2): 452 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Kerbel Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science, May 26, 2006; 312(5777): 1171 - 1175. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
